RETREG2 and acute myeloid leukemia: Furthermore, Aff-MAG2 specifically targets AML cells that express B7-H3 with high lethal potency and little to no collateral damage, making it a promising candidate for future personalized therapy in AML and other B7-H3-positive malignancies.